NCT05430243View on ClinicalTrials.gov

Empagliflozin as a Novel Therapy in Refractory Ascites

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

April 21, 2022

Primary Completion Date

November 12, 2022

Study Completion Date

November 12, 2022

Conditions
Ascites Hepatic
Interventions
DRUG

Empagliflozin 10 MG

once daily empagliflozin 10mg+/- diuretics

DRUG

Diuretics

diuretics as clinically indicated

Trial Locations (1)

21131

Alexandria University, Alexandria

All Listed Sponsors
lead

Alexandria University

OTHER